FibroGen, Inc (NASDAQ:FGEN) Director Jorma Routti sold 12,000 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $47.25, for a total value of $567,000.00. Following the completion of the sale, the director now directly owns 133,840 shares in the company, valued at $6,323,940. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of FibroGen, Inc (NASDAQ FGEN) opened at $44.50 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83. FibroGen, Inc has a 1-year low of $19.25 and a 1-year high of $60.15.
Large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in FibroGen by 15.1% in the 2nd quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock worth $187,612,000 after purchasing an additional 761,421 shares during the last quarter. BlackRock Inc. grew its holdings in shares of FibroGen by 12.3% in the 2nd quarter. BlackRock Inc. now owns 5,001,406 shares of the biopharmaceutical company’s stock valued at $161,545,000 after buying an additional 546,587 shares during the period. FMR LLC grew its holdings in shares of FibroGen by 96.9% in the 2nd quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after buying an additional 1,641,423 shares during the period. State Street Corp boosted its stake in FibroGen by 16.4% in the 2nd quarter. State Street Corp now owns 1,763,387 shares of the biopharmaceutical company’s stock worth $56,962,000 after purchasing an additional 248,922 shares during the period. Finally, Hillhouse Capital Management Ltd. boosted its stake in FibroGen by 75.0% in the 2nd quarter. Hillhouse Capital Management Ltd. now owns 1,750,000 shares of the biopharmaceutical company’s stock worth $56,525,000 after purchasing an additional 750,000 shares during the period. Institutional investors own 57.42% of the company’s stock.
Several brokerages have recently issued reports on FGEN. Leerink Swann reaffirmed an “outperform” rating and issued a $82.00 price target (up from $52.00) on shares of FibroGen in a research report on Tuesday, August 8th. William Blair reaffirmed an “outperform” rating on shares of FibroGen in a research report on Wednesday, August 9th. Citigroup raised their price target on FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a research report on Tuesday, August 8th. ValuEngine downgraded FibroGen from a “hold” rating to a “sell” rating in a research report on Friday. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $75.00 price target on shares of FibroGen in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. FibroGen has an average rating of “Buy” and an average price target of $65.67.
TRADEMARK VIOLATION WARNING: “FibroGen, Inc (FGEN) Director Jorma Routti Sells 12,000 Shares” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/05/fibrogen-inc-fgen-director-jorma-routti-sells-12000-shares.html.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.